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Abstract
Background: Generation of plasmin is a characteristic of tumor cells, promoting the degradation
of extracellular matrix, tumor progression and metastasis. The process is accelerated if
plasminogen and plasminogen activator are bound to their cell surface receptors.
Results: In this study we show that the monoclonal antibody that recognizes an epitope on the
cytokeratin 8 (CK8) ectoplasmic domain (anti-CK MAb) inhibits plasminogen activation mediated
by urokinase-type plasminogen activator (uPA) in MCF-7 and MCF-10A neoT cells. The
ectoplasmic domain of CK8 acts as a binding site for plasminogen, however, by using confocal
microscopy, we demonstrated that it is also co-localized with uPA. CK8, therefore, function also
as a receptor for uPA on the cell surface, and the presence of anti-CK MAb may prevent the binding
of uPA to a designated CK8 motif. The consequent inhibition of plasmin generation resulted in
changed cell morphology, enhanced cell adhesion to fibronectin, reduced invasion potential, and an
enhanced G1/S transition. Moreover, surface plasmon resonance analysis showed that the synthetic
dodecapeptide corresponding to the epitope sequence (VKIALEVEIATY), binds uPA in the
nanomolar range.
Conclusion: These novel findings suggest a model in which CK8, together with uPA, plasminogen
and fibronectin, constitutes a signaling platform capable of modulating cell adhesion/growth-
dependent signal transduction in breast tumor cells. Anti-CK MAb, which competes for the binding
site for uPA, could be used as an agent to reduce the invasive potential of breast tumor cells.
Background
Proteases are essential for invasion by tumor cells. For
this, they need to be activated, either on the tumor cell
surface or in the pericellular space. In breast cancer, urok-
inase type plasminogen activator (uPA), a serine protein-
ase, has been associated with an aggressive malignant
phenotype [1,2]. Cell surface uPA, bound to uPA receptor
(uPAR), activates plasminogen to plasmin, a central
player in breast cancer progression and metastasis. Plas-
min activates growth factors and protease cascades that
lead to the disruption of cell-cell and cell-extracellular
matrix adhesion via pericellular proteolysis of glycopro-
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teins [3,4]. Plasmin can also affect the cell phenotype by
activating or inactivating growth factors, and by modify-
ing growth factor receptors and adhesion receptors [5-7].
Plasminogen is activated on the cell surface much faster
than in solution, due to the presence of proteins that pro-
mote a plasminogen conformation more open to proteo-
lytic attack [8]. In addition to uPAR, cytokeratin 8 (CK8)
is an important plasminogen-binding protein in the
membrane of breast cancer cells. CK8 is an intermediate
filament protein and associates with CK18 to form an
insoluble matrix within the cell. However, the C-terminal
end of CK8 also penetrates the cellular membrane, as
shown for hepatocellular and breast carcinoma cells
[9,10]. CK8 is unique among cytokeratins in that it con-
tains a carboxyl-terminal lysine that can interact with the
lysine binding sites of plasminogen, although it is able to
bind plasminogen even when the C-terminal lysine is
mutated [11]. Plasminogen activation is promoted by tis-
sue type plasminogen activator (tPA), which can bind to
both components of the cytokeratin heterodimer, CK8/
CK18. Plasminogen and tPA cannot bind to CK8 at the
same time, but the binding of tPA to CK18 enhances the
binding of plasminogen to CK8 and its activation [11].
The CK8/CK18 complex modulates the signaling path-
ways intracellularly by binding kinases involved in signal
transduction. It integrates signals generated by stimulated
surface membrane receptors, such as insulin receptor and
integrin beta 1 receptor, and modulates their signal trans-
duction in appropriate reaction sequences. The absence of
CK8/CK18 in hepatocytes results in a phenotype that
attaches more rapidly to fibronectin and undergoes an
enhanced G1/S transition compared with wild-type hepa-
tocytes [12]. On the other hand, the cytoskeleton itself can
undergo rearrangements as a result of outside-in signals
triggered by fibronectin binding to cell surface receptors,
the integrins.
The aim of this study was to investigate the involvement
of CK8 in plasminogen activation, and consequently in
cell adhesion, invasion and signaling of breast tumor
cells. An anti-cytokeratin MAb directed against an epitope
on the ectoplasmic tail of CK8 was used to determine
whether it prevents uPA mediated activation of plasmino-
gen, resulting in enhanced adhesion of breast tumor cells
to fibronectin, reduced invasion, as well as changed mor-
phology and enhanced G1/S transition.
Results
Plasminogen expression in breast tumor cells
Plasminogen was detected by flow cytometry in MCF-10
A neoT cells that were cultured in serum-free medium
(Figure 1A). Staining with anti-plasminogen antibody
showed the presence of plasminogen on the plasma mem-
brane in non-permeabilized MCF-10 A neoT cells (Figure
1B). The staining pattern of plasminogen on the plasma
membrane of non-permeabilized MCF cells was shown,
by confocal microscopy, to be similar to that obtained
with anti-CK MAb [13]. Observation of several confocal
planes confirms that the staining follows the surface of the
cell.
uPA localization in breast tumor cells
The treatment of MCF10A neoT cells with anti-CK MAb
markedly affected breast tumor cell morphology. Whereas
non-treated cells, grown on a fibronectin-coated surface,
did not form typical epitheloid morphology but floated in
clusters in the medium, anti-CK MAb treated breast tumor
cells spread over the fibronectin-coated surface accompa-
nied by rearrangement of the cytoskeleton, as evident by
the reorganization of actin in bundles (Figures 2A and
2B).
uPA was co-localized with cytokeratins, detected with
anti-CK MAb, in MCF-10A neoT cells cultured on
fibronectin, which were not spread on the substratum but
loosely attached in a cell cluster. On the other hand, uPa
and cytokeratins were not co-localized in MCF-10A neoT
cells that were firmly attached to the substratum and that
exhibited epitheloid morphology (Figures 2C and 2D).
Binding of uPA to a cytokeratin sequence recognized by 
anti-CK MAb
The binding of uPA and plasminogen to the peptide VKI-
ALEVEIATY, deduced from the C-terminal region of CK1,
CK2, CK8, VK10, and recognized by anti-CK MAb [13],
was assessed by surface plasmon resonance analysis.
While the binding of plasminogen to the surface with
immobilized peptide was not significantly different from
that to the control flow cell surface lacking the peptide
(data not shown), uPA bound specifically to the peptide
in a concentration dependent manner, with a Ka of 9.8 nM
(Figure 3).
Additionally, the binding of uPA and anti-CK MAb was
tested simultaneously in ELISA on immobilized peptide
VKIALEVEIATY. The binding of anti-CK MAb was fol-
lowed by the secondary anti-mouse antibody, conjugated
to horse radish peroxidase or fluorescence dye Alexa Fluor
488. uPA and MAb competed for the binding to the pep-
tide in a dose response manner (see additional file 1).
Adhesion of breast tumor cells to fibronectin is increased 
by anti-CK MAb
When MCF-10A neoT cells were seeded on fibronectin,
they adhered more rapidly and to a greater extent in the
presence of anti-CK MAb than in its absence (Figure 4).
For instance, at 30 min post seeding, 67.7% of MCF-10A
neoT cells were already attached in the presence of theMolecular Cancer 2009, 8:88 http://www.molecular-cancer.com/content/8/1/88
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anti-CK MAb as compared to 21.7% in its absence. The
fact that the effect of anti-CK MAb was evident so quickly
indicates that it acts by binding to the cell surface epitope
and not by its intracellular activity. Even after 200 min,
only 48.8% of untreated cells were attached (Additional
File 2), while anti-CK MAb treated MCF-10A neoT cells
were all attached (Additional File 3). However, when uPA
was added to the culture medium, the anti-CK MAb-stim-
ulated adhesion of MCF-10A neoT cells was diminished
(54.5% after 200 min), demonstrating that increased plas-
min activity mediated by uPA reduces the adhesion of
breast tumor cells to fibronectin. Anti-CK MAb did not
alter cell adhesion to an uncoated surface, showing the
substrate-dependent effect of the MAb (Figure 5).
Invasion
Anti-CK MAb was tested for its effect on the invasion of
breast tumor cells through Matrigel. The addition of anti-
CK MAb to MCF-10A neoT cells strongly reduced the
degree of invasion compared to control cells (Figure 6).
This result can again be related to plasminogen activation
on breast cancer cells. However, the viability and prolifer-
ation of breast tumor cells on Matrigel were not affected
after 24 h by anti-CK MAb, as detected by MTS assay (data
not shown).
Effect of anti-CK MAb on the G1/S transition of breast 
tumor cells
Breast tumor cells need to be seeded on a substratum in
order to progress through the cell cycle in response to
growth stimulation. On seeding MCF neoT cells on
fibronectin in the presence of anti-CK MAb, more cells
entered S phase. The percentage of cells in S phase, as
detected by flow cytometry, was 4.2% for control cells and
10.0% for anti-CK MAb treated cells. In contrast, the G1/
S transition was not affected by anti-CK MAb when the
cells were cultured on an uncoated surface (Figure 7A).
Enhanced proliferation of breast tumor cells on fibronectin 
by anti-CK MAb
The extent of breast tumor cell proliferation on fibronec-
tin in the presence or absence of anti-CK MAb was
assessed using the CFSE reagent. The CFSE proliferation
assay does not depend on the metabolic activity of breast
tumor cells and enables detection of cells that have under-
gone cell division. The addition of anti-CK MAb enhanced
the proliferation of cells cultured on fibronectin from
77.3% to 94.2% (MCF10A neoT cells) and from 54.8% to
87.3% (MCF-7 cells). No enhancement was observed on
surfaces not covered with fibronectin (Figure 7B).
Plasminogen expression and localization in MCF10A neoT cells Figure 1
Plasminogen expression and localization in MCF10A neoT cells. (A) Flow cytometry histogram of MCF-10A neoT 
cells stained with anti-plasminogen antibody. Surface expression of plasminogen was evaluated in MCF10A neoT cells cultured 
on fibronectin in serum-free medium (bold line). The thin line represents the isotype control. (B) Plasminogen localization in 
MCF-10A neoT cells. Non-permeabilized breast cancer cells cultured on fibronectin-coated glass coverslips were stained with 
anti-plasminogen antibody. Plasminogen is distributed on the surface of cells (pointing arrows).Molecular Cancer 2009, 8:88 http://www.molecular-cancer.com/content/8/1/88
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Discussion
We have demonstrated that uPA is able to bind a particu-
lar motif on the CK8/CK18 complex expressed on the
plasma membrane of breast tumor cells, that is recognized
also by anti-CK MAb. The antibody hinders uPA binding
to the cell surface of MCF-7 and MCF-10A neoT breast
cells [13], resulting in lower plasmin generation, adhe-
sion, invasiveness and G1/S transition of breast tumor
cells.
Although plasminogen does not bind to the motif that
resembles the epitope of anti-CK MAb (data not shown),
anti-CK MAb significantly reduces plasminogen activa-
tion in MCF-7 and MCF-10A neoT cells [13]. Plasminogen
is shown to be expressed endogenously in these cells and
localized intracellularly as well as on the plasma mem-
brane. The activation of plasminogen to plasmin enables
degradation of the proteins of the extracellular matrix, a
process that enhances the invasive potential of tumor
cells. Plasminogen activation is enhanced if plasminogen
activator (uPA/tPA) and the substrate (plasminogen) are
in close juxtaposition on the cell surface. The most prom-
inent uPA binding receptor is uPAR (CD87). However,
plasminogen activation independent of uPAR suggests
that other uPA binding proteins exist on the plasma mem-
brane. On neutrophils, for example, M2 integrin recep-
tor binds uPA irrespectively of the presence of uPAR [14].
In this case, uPAR may serve as an enhancer of M2 bind-
ing, and uPAR, uPA, M2 and plasminogen may form a
multicontact complex on the cell surface. MCF-7 cells, for
example, express very low levels of cell surface uPAR com-
pared to the larger amount of cell surface bound plas-
minogen [15]. Our results show that CK8, the major
plasminogen receptor on breast tumor cells [16], may also
serve as a uPA binding protein and enhance uPA mediated
plasminogen activation. As shown by surface plasmon
resonance analysis, the interaction between uPA and CK8
is significant, since uPA binds the peptide VKIALEVEIATY,
deduced from the C-terminal region of CK8, in the
nanomolar range (Ka of 9.8 nM). This peptide, which also
binds strongly to the anti-CK MAb, contains a consensus
sequence, corresponding to the most conserved region
between D381 and E407 (CK8) in CK1, CK2, CK8, CK10
and CK18. Anti-CK MAb was shown to recognize these
CKs, therefore, we conclude that the epitope is identical,
independently of the exact amino acid sequence [13].
Expression of CK8 on the cell surface correlates with
increased invasiveness in vitro and in vivo [17,18] and may
predispose cell polarization and adhesion [19]. We have
shown that anti-CK MAb, by diminishing the uPA medi-
ated plasminogen activation in serum-free environment
[13], affects the de-adhesion-invasion processes of breast
tumor cells. The adhesion of these cells treated with anti-
CK MAb was greatly enhanced, due to the reduced pericel-
lular proteolysis of fibronectin, increasingly degraded in
the tumor environment by plasmin. This is consistent
with the findings of Tan et al. who showed that plasmino-
gen expression, restricted to cells with high invasion abil-
ity, is involved in cell dissociation, the first important step
in the invasion process [20]. The adhesion of MCF cells to
fibronectin is mediated via 1 integrin receptors, which
can be modified by plasmin in a way that affects the cell
phenotype [7,21]. Although we cannot exclude a direct
effect of plasmin on integrin chains, we suggest that the
anti-adhesive effect of plasmin results from the proteolytic
cleavage of fibronectin, similarly to the way that plasmin,
when generated by the uPA-dependent cell surface-associ-
ated pathway, abrogates the HaCaT cell binding functions
via cleavage of vitronectin and destruction of its cell bind-
ing function [22]. In contrast, anti-CK MAb did not affect
cell adhesion to the surface not coated with fibronectin.
Localization of uPA, cytokeratin and actin in MCF10A neoT  cells Figure 2
Localization of uPA, cytokeratin and actin in 
MCF10A neoT cells. Colocalization of anti-uPA antibody 
and anti-CK MAb (A). MCF-10A neoT cells were stained 
with anti-uPA MAb (green fluorescence, Alexa-488) and anti-
CK MAb (red fluorescence, Alexa-555) and imaged sequen-
tially in a line-interlace mode to eliminate cross talk between 
the channels. The threshold level for this display was set arbi-
trarily. Pixels above the threshold in both channels (blue 
color, right panel) and the contour plot are shown for 
MCF10A neoT cell cluster (inset C) demonstrating strong 
co-localization in contrast to adherent MCF-10A neoT cells 
(B). Anti-CK Mab triggered actin reorganization in MCF-10A 
neoT cells. MCF-10A neoT cells, treated (C) and non-
treated (D) with anti-CK MAb, were cultured on fibronectin 
for 2 h and stained with phalloidin. Actin bundles are seen in 
anti-CK8 MAb treated cells but not in non-treated cells.Molecular Cancer 2009, 8:88 http://www.molecular-cancer.com/content/8/1/88
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Our results further show that, in breast tumor cells cul-
tured on fibronectin in serum free medium, anti-CK MAb
reduces cell cluster formation and promotes cell polariza-
tion associated with actin reorganization. This is consist-
ent with the observations that, in the presence of uPA or
plasmin, MCF-7 breast tumor cells begin to retract and
form solid tumor cell spheroids [23]. The spontaneous
formation of the spheroids starts after supplementing the
culture medium with an outdated source of human serum
containing uPA and plasminogen [23].
Anti-CK MAb treated breast tumor cells cultured on
fibronectin, but not on uncoated surface, also exhibited
enhanced proliferation. The latter can be attributed to an
increased mitogenic signal delivered by fibronectin,
where the activating signal is mediated by 1 integrin
receptor. The signaling reactions activated by 1 integrins
include focal adhesion kinase (FAK)-Src and MAPK path-
ways, and generate sustained activation of the PI3K-Akt
pathway, a property that could be important for anchor-
age-dependent survival of cells [24]. MCF-7 cell-fibronec-
tin interaction induces the re-entry of MCF-7 cells into S
phase, and prevents them from undergoing serum depri-
vation induced apoptosis [25]. Anti-CK MAb increases
adhesion of breast cancer cells to fibronectin, thereby pro-
moting their G1/S transition. These novel findings suggest
a model by which CK8, along with plasminogen-see earlier
comment and fibronectin, constitutes a signaling platform
capable of modulating cell adhesion/growth-dependent
signal transduction. A similar effect was observed in CK8-
null hepatocytes, which attach more rapidly but spread
more slowly on a fibronectin substratum. Loss of CK8/
CK18 also leads to decreased size, reduced rate of protein
synthesis, and an enhanced G1/S transition in hepato-
cytes [12]. The analogy between hepatocytes and the
MCF-7/MCF-10A neoT used in our experiments is not sur-
prising, considering that CK8-mediated plasmin activa-
tion has been reported on hepatocytes and hepatocellular
carcinoma cells, as well as on certain breast tumor cells
[19].
Conclusion
Anti-CK MAb, that recognizes the epitope on the ectoplas-
mic tail of CK8 present on the plasma membrane of the
breast tumor cells, prevents the binding of uPA to cytoker-
atin and, consequently, the activation of plasminogen to
plasmin. Anti-CK MAb could thus be used as an agent to
reduce the invasive potential of breast tumor cells,
uPA binding to dodecapeptide VKIALEVEIATY Figure 3
uPA binding to dodecapeptide VKIALEVEIATY. Association and dissociation curves of uPA binding to VKIALEVEIATY 
peptide, obtained by surface plasmon resonance (from the bottom up, uPA at 10 nM, 20 nM and 50 nM). A Ka of 9.8 nM was 
calculated, using the 1:1 binding with drifting baseline model.Molecular Cancer 2009, 8:88 http://www.molecular-cancer.com/content/8/1/88
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whereas the synthetic peptide, resembling the epitope,
may regulate uPA activity.
Methods
Cell culture
MCF-10A neoT cells were provided by Prof. Bonnie F.
Sloane (Wayne State University, Detroit, MI). The original
human breast epithelial cell line (MCF-10) was trans-
formed with neomycin resistance gene and c-Ha-ras onco-
gene, to give a highly invasive cell phenotype. MCF-7 cells
were obtained from ATCC (HTB 22). Cells were cultured
in monolayers to 80% confluence in DMEM/F12 medium
supplemented with 12.5 mM HEPES, 2 mM glutamine,
5% fetal bovine serum (FCS), insulin, hydrocortisone,
epidermal growth factor and antibiotics at 37°C in a
humidified atmosphere containing 5% CO2. The cells
were maintained in serum-free medium for 24 h before
being used in assays. Cells were washed with PBS, pH 7.4
and detached from culture flasks with 0.05% trypsin and
0.02% EDTA in PBS, pH 7.4. The viability of cells in the
experiments was at least 90%, as determined by staining
with nigrosin.
Antibody preparation
Anti-CK MAb, a mouse monoclonal antibody, was raised
against soluble membrane proteins of MCF-7 human
invasive ductal breast carcinoma. Using immunocyto-
chemical analysis, its staining was detected predomi-
nantly in primary breast carcinomas and in metastatic
lymph nodes [13,26]. The antibody recognizes a specific
cytokeratin profile (cytokeratins 1, 2, 8, 10, 18) in MCF-7
and MCF-10A neoT breast cancer cell lines [13], as deter-
mined by 2D electrophoresis, immunoblotting and mass
spectroscopy. Hybridoma cells for antibody isolation
were cultured in DMEM medium supplemented with 2
mM glutamine, 13% FCS and antibiotics, at 37°C in a
humidified atmosphere containing 5% CO2. The anti-
body was isolated by affinity chromatography on Protein
A Sepharose using standard procedures. On MCF-7 and
MCF-10A neoT it was demonstrated that the antibody
inhibited the generation of plasmin in a dose dependent
manner [13].
Immunofluorescence
For flow cytometry, MCF-10A neoT cells were grown for
24 hours in serum free medium and afterwards cultured
on 12-well plates pre-coated with fibronectin (Corning
Costar). Cells were harvested and fixed in 4% paraformal-
dehyde for 30 min, and permeabilized for 10 minutes
with Triton-X 100. Non-specific staining was blocked for
30 minutes with 3% BSA in phosphate buffered saline
(PBS), pH 7.4. Cells were incubated with 5 g/mL goat
anti-plasminogen polyclonal antibody in blocking buffer
for 1 hour on ice. Afterwards, the cells were washed with
PBS and incubated with Alexa-488 labeled anti-goat sec-
ondary antibody in blocking buffer for 1 hour on ice.
Alexa-488-IgG1 was used for isotype control. Cells were
washed and analyzed with FACS Calibur (Becton Dickin-
son, NJ).
For confocal microscopy, glass coverslips were pre-treated
with 20% sulfuric acid, followed by 10 M NaOH, and
washed with distilled water and ethanol before use. They
were coated with 1 g/mL fibronectin in carbonate buffer,
pH 9.6 overnight at 4°C. For immunofluorescence detec-
tion, MCF-10A neoT cells were cultured on either
fibronectin-coated or uncoated coverslips for 24 hours.
Cells were fixed with 2% paraformaldehyde at room tem-
perature for 40 minutes, then permeabilized with 0.05%
Triton-X 100. To preserve membrane associated compo-
nents and foreclose cytoplasmic staining, some samples
were not permeabilized with Triton-X 100. Non-specific
staining was blocked with 3% BSA in phosphate buffer
saline (PBS), pH 7.4, for 1 hour. After 1.5 hour of incuba-
tion with anti-CK MAb and either rabbit anti-uPA polyclo-
nal antibody or goat anti-plasmin(ogen) polyclonal
antibody (Santa Cruz Biotechnology, CA), cells were
washed with PBS. Secondary Alexa-488 labeled anti-rab-
bit or Alexa-488 labeled anti-goat and Alexa-555 labeled
anti-mouse antibody were incubated for 1 hour in block-
ing buffer and afterwards washed with PBS. Actin was
labeled with phalloidin-tetramethylrhodamine B isothio-
cyanate conjugate (Fluka) (500 ng/mL) for 30 min at
room temperature in anti-CK MAb treated or un-treated
Adhesion of MCF-10A neoT cells to fibronectin in the pres- ence of anti-CK MAb and uPA Figure 4
Adhesion of MCF-10A neoT cells to fibronectin in the 
presence of anti-CK MAb and uPA. MCF10A neoT cells 
were cultured on a fibronectin coated surface in the absence 
or presence of anti-CK MAb and/or uPA. The percentage of 
adherent cells was assessed with MTS assay. The time course 
of adhesion to the fibronectin surface is shown (See also 
Video S1 and S2). Samples were analyzed in quadruplicate 
and each point is the mean of at least three independent 
experiments.Molecular Cancer 2009, 8:88 http://www.molecular-cancer.com/content/8/1/88
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cells, then washed with PBS. Prolong Antifade kit (Molec-
ular Probes, CA) was used for mounting coverslips on
glass slides. Fluorescence microscopy was performed
using a Carl Zeiss LSM 510 confocal microscope. Alexa
488 and FITC were excited with an argon (488 nm) laser
and Alexa 546 with a He/Ne (543 nm) laser. Emission was
filtered using narrow band 505-530 nm or LP 560 nm fil-
ters, respectively. Images were analyzed using Carl Zeiss
LSM image software 3.0.
Surface plasmon resonance
The binding of uPA to the peptide VKIALEVEIATY (Doljak
et al., 2008) was monitored using a Biacore X system
(Biacore, Sweden). The assay was performed on a CM5
sensor chip (BR-1003-98 BIAcore). VKIALEVEIATY was
immobilized at a flow rate of 1 L/min for 10 minutes
(300 RU). The flow cell was then washed with 5 L of 10
mM glycine buffer (pH 2.2) at a flow rate of 30 L/min.
The second flow cell was used as the reference cell. Identi-
cal wash cycles were used to regenerate the dodecapeptide
Anti-CK MAb changes the morphology of MCF-10A neoT cells cultured on fibronectin Figure 5
Anti-CK MAb changes the morphology of MCF-10A neoT cells cultured on fibronectin. Photomicrographs of 
MCF-10A neoT cells cultured for 24 h on uncoated (below) or fibronectin-coated surfaces (above) are shown for control and 
anti-CK8 MAb treated cells. Anti-CK MAb enables the adhesion to fibronectin of MCF-10A neoT cells, but not control cells, 
which form cell clusters. In contrast, both control and anti-CK MAb treated cells adhere to uncoated surface.Molecular Cancer 2009, 8:88 http://www.molecular-cancer.com/content/8/1/88
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surface between the assays. uPA was prepared in PBST
buffer (PBS with 0.05% Tween 20). All steps were per-
formed at 25°C with a flow rate of 1 L/min in 1% PBST
running buffer. 5 L of uPA was injected for each assay.
Cell invasion assay
Transwell plates (Corning Costar, MD) with 12-mm poly-
carbonate filters and 12 m pore size, were used to test the
effect of anti-CK MAb on invasion of breast cancer cells.
25 l of 100 g/mL fibronectin (Sigma, Germany) was
applied on the lower side of the filters and left for one
hour in a laminar hood to dry. The upper sides of the fil-
ters were then coated with 100 L of 1 mg/mL Matrigel
(Becton Dickinson, NJ), 100 L of DMEM was added, and
the filters left at 37°C for one hour. The upper compart-
ments were then filled with 500 L of MCF-10A neoT cells
(4 × 105 cells/mL) while 1.5 mL of medium was added to
the lower compartments. Anti-CK MAb (1 M) was added
to the compartments. The control cells were plated with-
out the addition of anti-CK MAb. To determine the per-
centage of invasion of treated and control cells, the
separate lower compartments were filled with 500 L of
MCF-10A neoT cells (4 × 105 cells/mL) and the plate incu-
bated for 24 hours at 37°C and 5% CO2. The lower com-
The effect of anti-CK MAb on cell cycle (A) and proliferation (B) of breast tumor cells cultured on fibronectin Figure 7
The effect of anti-CK MAb on cell cycle (A) and proliferation (B) of breast tumor cells cultured on fibronectin. 
MCF-10A neoT and MCF-7 cells were cultured in serum-free medium in the absence or presence of anti-CK MAb. After 24 h 
they were harvested and analyzed for cell cycle status by flow cytometry. The percentage of anti-CK MAb treated and 
untreated cells in S phase is given (A, top). The representative histogram used to determine the percentage of distinctive cell 
populations is shown at the bottom. For the proliferation assay, MCF-7 cells were labeled with CFSE reagent and cultured for 
48 h in the presence or absence of anti-CK MAb. Proliferation threshold was set according to CFSE labeled cells analyzed 
immediately after labeling (B, bottom). The percentage of proliferating cells of the PIneg population is given (B, top). Results rep-
resent at least three independent assays. P values of < 0.05 are marked with *, and P values < 0.001 with **.
Anti-CK MAb reduces the invasiveness of MCF-10A neoT  cells Figure 6
Anti-CK MAb reduces the invasiveness of MCF-10A 
neoT cells. The degree of invasion of Matrigel by MCF-10A 
neoT cells is shown in the presence and absence of anti-CK 
MAb. It is presented as the percentage of invasion of MCF-
10A neoT cells to the lower compartment of a Transwell 
chamber. Bars represent mean percentages of migrated cells 
± s.d. P values < 0.001 are marked with **.Molecular Cancer 2009, 8:88 http://www.molecular-cancer.com/content/8/1/88
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partments were washed with PBS and the cells detached
with 0.05% trypsin and 0.02% EDTA in PBS, pH 7.4. Cells
from the lower compartments were transferred separately
to Eppendorf tubes and centrifuged at 1500 rpm for 5
minutes. They were resuspended in culture medium and
transferred to 96-well plates. The Cell Proliferation Assay
CellTiter 96® One Solution from the (3-(4,5-dimethylthi-
azol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium) MTS (colorimetric assay, Promega,
WI) was added and the plate incubated for an additional
2 hours. The absorbance, A, of the formazan product was
measured at 590 nm. Invasion was recorded as the per-
centage of the cells that penetrated the Matrigel-coated fil-
ters:
Cell adhesion assay
A 96-well culture plate was pre-coated with 50 L of
fibronectin (1 g/mL) in carbonate buffer, pH 9.6, over-
night at 4°. Wells were then washed once with PBS and
incubated with 1% BSA in PBS for 30 min at room tem-
perature. MCF-10A neoT cells were harvested, washed
with PBS and resuspended in the serum-free medium.
Anti-CK MAb was added to the medium at a final concen-
tration 1 M. 50 L of MCF-10A neoT cell suspension was
added to each well of a 96-well culture plate (TPP, Swit-
zerland) pre-coated with fibronectin. Cells were allowed
to attach for 15 min, 45 min, 1.5 h, 3 h and 5 h, after
which wells were washed twice with PBS, and 100 L of
complete growth medium was added. The assay was per-
formed in quadruplicate. Control wells were washed with
50 L of medium. Finally, CellTiter 96® One Solution was
added, formazan absorbance measured, and cell adher-
ence was calculated from the equation:
where the absorbance of formazan were determined for
cells washed at different time points (Atx) and for cells not
washed (Acontrol).
Differential interference contrast images were taken with
an Olympus IX 81 motorized inverted microscope and
Cell® software.
Cell cycle analysis
A 12-well culture plate was pre-coated with 250 L of
fibronectin (1 g/mL) in carbonate buffer, pH 9.6 over-
night at 4°C. Wells were washed once with PBS and incu-
bated with 1% BSA in PBS for 30 min at room
temperature. MCF-10A neoT cells were harvested, washed
with PBS and resuspended in the serum-free medium in
the presence of anti-CK MAb (1 M), while the antibody
was not added to control wells. MCF-10A neoT cells (1 ×
105 cells, 500 L) were added to a 12-well culture plate
(TPP) pre-coated with fibronectin. Control wells were not
pre-coated with fibronectin. Cells were cultured for either
48 h or 72 h, washed twice with PBS and detached with
0.05% trypsin and 0.02% EDTA in PBS, pH 7.4. Cells were
centrifuged at 1500 rpm for 5 min, resuspended in ice-
cold ethanol and incubated at -20°C for 45 min. Cells
were then centrifuged again and propidium iodide and
RNAse added to final concentrations of 40 g/ml and
0.1%. Cells were incubated for 30 min at 37°C, washed
with PBS and analyzed for DNA content. Flow cytometry
was performed on a FACS Calibur (Becton Dickinson,
NJ).
Cell proliferation assay
A 12-well culture plate was pre-coated overnight with 250
L of fibronectin in carbonate buffer, pH 9.6 (1 g/mL),
at 4 °C. Wells were washed once with PBS and incubated
with 1% BSA in PBS for 30 min at room temperature.
MCF-10A neoT cells were harvested, washed with PBS,
labeled with CFSE (5-carboxyflourescein diacetate succin-
imidyl ester) cell tracing reagent (Molecular Probes, CA)
according to the manufacturer's protocol, and re-sus-
pended in the serum-free medium, with or without anti-
CK MAb (1 M). MCF-10A neoT cells (1 × 105 cells, 500
L) were added to a 12-well culture plate (TPP) pre-coated
with fibronectin. Control wells were not pre-coated with
fibronectin. Cells were cultured for either 48 h or 72 h.
Wells were then washed twice with PBS and cells detached
with 0.05% trypsin and 0.02% EDTA in PBS, pH 7.4. The
threshold for proliferating cells was set according to MCF-
10A neoT cells measured for CFSE fluorescence intensity
at the beginning of the assay. Flow cytometry was per-
formed on a FACS Calibur (Becton Dickinson).
Statistical analysis
SPSS PC software package (Release 13.0) was used for sta-
tistical analysis. The difference between the groups was
evaluated using the non-parametric Mann-Whitney test. P
values of < 0.05 were considered to denote statistical sig-
nificance.
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concentration of anti-CK MAb was 6.7 nM. Secondary goat-antimouse 
antibody conjugated to HRP was used for the detection of bound anti-CK 
MAb.
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S2 - Adhesion of MCF-10A neoT cells to fibronectin in the absence of 
anti-CK MAb. Video showing adhesion of MCF-10A neoT cells to 
fibronectin in the absence of anti-CK MAb.
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S3 - Adhesion of MCF-10A neoT cells to fibronectin in the presence of 
anti-CK MAb. Video showing the adhesion of MCF-10A neoT cells to 
fibronectin in the presence of anti-CK MAb.
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[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-88-S3.MOV]